Former Abbot Laboratories Sales Manager for Middle East and Africa Brings industry Experience to Endexx Corporation
CAVE CREEK, AZ, Sept. 06, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Endexx® Corporation (OTCQB: EDXC), a provider of innovative plant-based wellness and nutritional products, today announced it has appointed Ahmed Itani to lead HYLA’s marketing efforts in The Middle East region.
A seasoned professional with an impressive track record in the corporate world, Itani boasts 14 years of commercial healthcare sales experience and is a dynamic team player who has consistently excelled in driving business growth and fostering strong client relationships.
“Mr. Itani’s wealth of experience, strategic vision, and commitment to success makes him a perfect match to lead HYLA’s marketing efforts in The Middle East,” said Todd Davis, CEO of Endexx Corporation. “We are excited to welcome Mr. Itani and continue to expand the HYLA team as the demand for plant-based products grows throughout the world.”
Mr. Itani’s career began at Abbott Laboratories, where he took charge of managing the commercial activities in The Middle East region. Through meticulous customer relationship management and astute distributor oversight, Itani played a key role in expanding Abbott Laboratories’ presence in this vital market.
“Today I am embarking on an exciting new chapter in the ever-evolving industry of alternative vaping,” said Itani, Director of Marketing for HYLA Middle East. “As an integral part of HYLA Holdco USA, I am on a mission to elevate the business to unprecedented heights.”
www.endexx.com & www.cbdunlimited.com
About Endexx Corporation
Endexx Corporation develops and distributes all natural, plant-derived wellness products and topical skincare products. Its products vary from balms, creams, lotions, butters, masks, scrubs, and oils, all with the shared purpose of healthy skin and grooming wellness. The science behind these products involves a decade of clinical research in the field and lab work to provide functional formulation with ingredients for optimal absorption and support of skin health. www.endexx.com
Hyla currently markets its proprietary non-nicotine, guarana and L-Dopa-based vape products in a wide variety of flavors. The Hyla device is the first non-nicotine vape product to be produced in this manner in the United States and provides an unprecedented 4,500 puffs per device. Hyla is currently being distributed in 10 countries and has signed distribution agreements with an additional nine countries. www.tryhyla.com
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
We caution that any forward-looking statements (as such term is defined in the U.S. Private Securities Litigation Reform Act of 1995) contained in this press release or made by us, our management, or our spokespeople involve risks and uncertainties and are subject to change based on various factors, many of which are beyond our control. Accordingly, our future performance and financial results may differ materially from those expressed or implied in any such forward-looking statements. Forward-looking statements include, without limitation, statements regarding our future operating results, the implementation and impact of our strategic plans, and our ability to meet environmental, social, and governance goals. Words such as “estimate,” “commit,” “target,” “goal,” “project,” “plan,” “believe,” “seek,” “strive,” “expect,” “anticipate,” “intend,” “potential” and any similar expressions may identify forward-looking statements. Risks associated with the following factors, among others, could affect our financial performance and cause actual results to differ materially from those expressed or implied in any forward-looking statements.
Except as may be required by law, we assume no obligation and do not intend to make publicly available any update or other revisions to any of the forward-looking statements contained in this press release to reflect circumstances existing after the date of this press release or to reflect the occurrence of future events, even if experience or future events make it clear that any expected results expressed or implied by those forward-looking statements will not be realized. More information on potential factors that could affect our results is included “Risk Factors” in our amended Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on June 9, 2023.
No Offer or Solicitation. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and, where applicable, the requirements under the securities laws of any other applicable jurisdiction.
For further information, please contact:
Endexx Corporation
IR@Endexx.com
480-595-6900
